
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 1, 2003
Date of Report (Date of earliest event reported)

ORAGENICS, INC.
(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

333-100568
(Commission
File Number)

59-3410522
(IRS Employer
Identification No.)

12085 Research Drive
Alachua, Florida 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

None
(Former name or former address, if changed since last report.)

ITEM 7. FINANCIAL INFORMATION AND EXHIBITS

Exhibit No.	Description
--------------------	--------------------

99.1	Press Release
------	---------------

ITEM 9. REGULATION FD DISCLOSURE

David J. Gury, retired founding CEO and current Chairman of the Board of Nabi Biopharmaceuticals, has been appointed to the Company's Board of Directors.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 1st day of October, 2003.

ORAGENICS, INC.

(Registrant)

BY: /s/ Paul Hassie

Paul Hassie

Principal Financial Officer

Exhibit 99.1

Contact:

Mento A. "Chuck" Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

FOR IMMEDIATE RELEASE

Oragenics, Inc. Names New Board Member

David J. Gury retired Nabi Biopharmaceuticals CEO Appointed to Board

Alachua, FL (October 6, 2003) - Oragenics, Inc. (TSX-V: ORA.U), today announced that David J. Gury, retired founding CEO and current Chairman of the Board of Nabi Biopharmaceuticals, has been appointed to the Company's Board of Directors. Mr. Gury brings to Oragenics more than 30 years executive experience in the pharmaceutical and biotechnology industries.

"We are privileged to have attracted such a talented industry executive to our Board of Directors," said Mento A. "Chuck" Soponis, C.E.O. of Oragenics. "David brings a unique combination of entrepreneurial and executive experience at the most senior levels in the industry. We look forward to benefiting from his insight and seasoned know-how as we continue to move forward in developing our key products to build a successfully competitive biotechnology company.

Mr. Gury, 64, joined Nabi, a biopharmaceutical company that develops and commercializes vaccines and therapies that prevent and treat infectious, autoimmune and addictive diseases, as President and Chief Operating Officer in 1984. In 1992 he was elected Chairman of the Board, Chief Executive Officer and President. During his tenure, the Company successfully transitioned from a plasma supplier into a fully integrated biopharmaceutical company. Prior to joining Nabi, he spent his career with Abbott Laboratories and its spin out company, Alpha Therapeutics Corporation, in various administrative and executive positions.

He is a member of the Florida Emerging Technology Commission; Chairman of the Florida Research Consortium; and past Chairman and a member of BioFlorida. Mr. Gury earned his M.B.A. at the University of Chicago.

Oragenics, Inc. is an emerging biotechnology research and development company that began operations in 1999. Located in Alachua, Florida at the University of Florida's Sid Martin Biotechnology Development Incubator, Oragenics is developing three new healthcare products. The most advanced product is an oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The second product in pre-clinical development is a broad-spectrum antibiotic. Oragenics is also developing a probiotic product to maintain oral health. For more information about Oragenics, please consult the Company's website at www.oragenics.com.

#####

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.
